NCT00667953View on ClinicalTrials.gov

Study of Temzolomide and Gleevec in Advanced Melanoma

PHASE1/PHASE2TerminatedINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

January 31, 2003

Primary Completion Date

March 9, 2011

Study Completion Date

March 9, 2011

Conditions

MelanomaAdvanced Melanoma

Interventions

DRUG

Gleevec

Gleevec (600 mg) daily.

DRUG

Temodar

Temzolomide (1000 mg/m2) over 5 days on a 28 day cycle.

Trial Locations (1)

19104

Abramson Cancer Center at University of Pennsylvania, Philadelphia

Sponsors

Collaborators (1)

Novartis Pharmaceuticals

All Listed Sponsors

collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Abramson Cancer Center at Penn Medicine

OTHER